News
ICCM
0.6789
-3.41%
-0.0240
IceCure Medical Announces Special General Meeting for Key Votes
TipRanks · 1d ago
Weekly Report: what happened at ICCM last week (1124-1128)?
Weekly Report · 3d ago
Weekly Report: what happened at ICCM last week (1117-1121)?
Weekly Report · 11/24 10:27
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/20 21:06
Promising Growth and Strategic Expansion Justify Buy Rating for Icecure Medical
TipRanks · 11/20 20:35
IceCure Medical Reports Q3 2025 Financial Results
TipRanks · 11/20 04:02
IceCure Medical’s Earnings Call Highlights Growth Potential
TipRanks · 11/20 00:09
IceCure Medical Gains FDA Approval for ProSense® in Breast Cancer Treatment
TipRanks · 11/19 14:27
CORRECTION: Icecure Medical Q3 EPS $(0.06) Misses $(0.05) Estimate, Sales $850.000K Beat $714.000K Estimate
Benzinga · 11/19 14:14
Icecure Medical Q3 EPS $0.06 Beats $(0.05) Estimate, Sales $850.000K Beat $714.000K Estimate
Benzinga · 11/19 14:08
IceCure Medical reports nine-month financial results through September 2025
Reuters · 11/19 14:05
IceCure Medical reports nine months ended results
Seeking Alpha · 11/19 13:56
IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer
Reuters · 11/19 13:54
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
PR Newswire · 11/19 13:54
Earnings Scheduled For November 19, 2025
Benzinga · 11/19 11:11
What's Next: Icecure Medical's Earnings Preview
Benzinga · 11/18 16:02
IceCure Medical’s ProSense system receives regulatory approval in Switzerland
TipRanks · 11/18 14:42
IceCure Medical’s ProSense® System Gains Swiss Approval for Cancer Treatment
TipRanks · 11/18 14:07
IceCure Medical Receives Registration, Approval For Its ProSense System For Distribution By Swissmedic
Benzinga · 11/18 13:45
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
PR Newswire · 11/18 13:30
More
Webull provides a variety of real-time ICCM stock news. You can receive the latest news about Icecure Medical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.